| Detected | Trial | Change |
|---|---|---|
| 2026-06-06 | NCT05552222 A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and… |
Trial sites expanded: 265 -> 270 locations |
| 2026-06-05 | NCT07581704 Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody… |
Recruitment opened |
| 2026-06-05 | NCT07581704 Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody… |
date change Primary completion pushed: 2029-05-01 -> 2029-06-01 |
| 2026-06-05 | NCT07581704 Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody… |
date change Completion pushed: 2029-09-01 -> 2029-10-01 |
| 2026-06-04 | NCT06208150 A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and… |
date change Completion pushed: 2028-03-31 -> 2028-12-31 |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT05552222 | A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and… | Multiple Myeloma | Recruiting |
| NCT06208150 | A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and… | Multiple Myeloma | Recruiting |
| NCT05455320 | A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With… | Multiple Myeloma | Active, Not Recruiting |
| Phase 2 | |||
| NCT06100237 | Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical… | Multiple Myeloma | Recruiting |
| NCT06066346 | A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell… | Multiple Myeloma | Recruiting |
| NCT07107529 | Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab… | Multiple Myeloma (MM) | Recruiting |
| NCT05972135 | Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma | Multiple Myeloma | Recruiting |
| NCT06993675 | Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With… | Multiple Myeloma | Recruiting |
| NCT04634552 | A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma | Hematological Malignancies | Recruiting |
| NCT06500884 | A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events | Multiple Myeloma | Recruiting |
| NCT06353022 | Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With… | Multiple Myeloma | Active, Not Recruiting |
| NCT05849610 | Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk… | High-Risk de Novo Multiple Myeloma | Active, Not Recruiting |
| NCT06550895 | A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants… | Multiple Myeloma | Active, Not Recruiting |
| NCT06577025 | A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab… | Multiple Myeloma | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT04586426 | A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed… | Multiple Myeloma | Active, Not Recruiting |
| Phase 1 | |||
| NCT07093554 | Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by… | Relapse Multiple Myeloma | Recruiting |
| NCT06348108 | Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory… | Multiple Myeloma | Recruiting |
| NCT07032714 | Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma | Relapsed Refractory Multiple Myeloma (RRMM) | Recruiting |
| NCT07581704 | Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody… | Multiple Myeloma | Recruiting |
| NCT03399799 | Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple… | Hematological Malignancies | Active, Not Recruiting |
| NCT04108195 | A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell… | Multiple Myeloma | Active, Not Recruiting |
| NCT05050097 | A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple… | Multiple Myeloma | Active, Not Recruiting |
| NCT05338775 | A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death… | Relapsed/ Refractory Multiple Myeloma | Active, Not Recruiting |
| Not specified | |||
| NCT07499323 | Talquetamab in Patients With Refractory Generalized Myasthenia Gravis | Myasthenia Gravis (MG) | Not Yet Recruiting |